Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 112-117, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kimura, M.
Right arrow Articles by Amino, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kimura, M.
Right arrow Articles by Amino, N.
Related Collections
Right arrow Clinical Immunology
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2000;46:112-117.)
© 2000 American Association for Clinical Chemistry, Inc.

Articles

Enzyme Immunoassay for Autoantibodies to Human Liver-Type Arginase and Its Clinical Application

Masahiro Kimura1, Ke-Ita Tatsumi1, Hisato Tada1, Masaki Ikemoto2, Yoshihiro Fukuda2, Akira Kaneko3, Michio Kato3, Yoh Hidaka1 and Nobuyuki Amino1,a

1 Department of Laboratory Medicine, Osaka University Medical School, Osaka 565-0871, Japan.

2 College of Medical Technology, Kyoto University, Kyoto 606-8507, Japan.

3 Department of Gastroenterology, Osaka National Hospital, Osaka 540-0006, Japan.
a Address correspondence to this author at: Department of Laboratory Medicine, Osaka University Medical School D2, Osaka 565-0871, Japan. Fax 81-6-6879-3239; e-mail namino{at}labo.med.osaka-u.ac.jp

Background: Arginase is an enzyme of the urea cycle, and one of the two isoenzymes is the liver-type enzyme. We examined serum autoantibodies to this liver-type enzyme in patients with hepatitis.

Methods: Antibodies to recombinant human liver-type arginase were measured by ELISA in 95 patients and 55 healthy controls.

Results: The mean absorbance values in the ELISA assays of patients with definite autoimmune hepatitis (n = 11; P <0.0001), probable autoimmune hepatitis (n = 31; P <0.0001), and hepatitis C (HCV; n = 20; P <0.01) were significantly different from those of healthy controls, but the values in patients with hepatitis B (HBV; n = 23) and other autoimmune diseases (n = 10) were not significantly different from those of healthy controls. When the cutoff was fixed at the upper 95th percentile of the absorbance value in healthy controls, positive reactions were found in 18.2%, 32.3%, 20.0%, 13.0%, and 10.0% of patients with definite autoimmune hepatitis, probable autoimmune hepatitis, HCV hepatitis, HBV hepatitis, and other autoimmune diseases, respectively. All of these positive reactions were abolished by inhibition of serum with recombinant antigen. The specificity and sensitivity of this ELISA were 96% and 29%, respectively. The intraassay and interassay coefficients of variation were 2.3–7.5% and 9.8–11%, respectively. There was no relationship between these antibodies and anti-nuclear, anti-smooth muscle, or anti-cytochrome P450IID6 antibodies.

Conclusions: The ELISA for anti-liver-type arginase autoantibody improved the detectability of autoimmune hepatitis when compared with established assays for liver-specific autoantibodies.




The following articles in journals at HighWire Press have cited this article:


Home page
 Hum Exp ToxicolHome page
D E Amacher
A toxicologist's guide to biomarkers of hepatic response
Human and Experimental Toxicology, May 1, 2002; 21(5): 253 - 262.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.